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Abstract
Background: Accumulation of aberrant proteins to form Lewy bodies (LBs) is a hallmark of Parkinson’s disease
(PD). Ubiquitination-mediated degradation of aberrant, misfolded proteins is critical for maintaining normal cell
function. Emerging evidence suggests that oxidative/nitrosative stress compromises the precisely-regulated network
of ubiquitination in PD, particularly affecting parkin E3 ligase activity, and contributes to the accumulation of toxic
proteins and neuronal cell death.
Results: To gain insight into the mechanism whereby cell stress alters parkin-mediated ubiquitination and LB
formation, we investigated the effect of oxidative stress. We found significant increases in oxidation (sulfonation)
and subsequent aggregation of parkin in SH-SY5Y cells exposed to the mitochondrial complex I inhibitor 1-methyl-
4-phenlypyridinium (MPP
+), representing an in vitro cell-based PD model. Exposure of these cells to direct oxidation
via pathological doses of H2O2 induced a vicious cycle of increased followed by decreased parkin E3 ligase activity,
similar to that previously reported following S-nitrosylation of parkin. Pre-incubation with catalase attenuated H2O2
accumulation, parkin sulfonation, and parkin aggregation. Mass spectrometry (MS) analysis revealed that H2O2
reacted with specific cysteine residues of parkin, resulting in sulfination/sulfonation in regions of the protein similar
to those affected by parkin mutations in hereditary forms of PD. Immunohistochemistry or gel electrophoresis
revealed an increase in aggregated parkin in rats and primates exposed to mitochondrial complex I inhibitors, as
well as in postmortem human brain from patients with PD with LBs.
Conclusion: These findings show that oxidative stress alters parkin E3 ligase activity, leading to dysfunction of the
ubiquitin-proteasome system and potentially contributing to LB formation.
Background
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder, affecting approximately
1% of the population over age 60 [1,2]. Histopathology of
PD brains shows a progressive loss of dopaminergic (DA)
neurons in the substantia nigra and the formation of
cytoplasmic inclusions known as Lewy bodies (LBs) and
Lewy neurites (LN) [3]. LBs/LNs contain a number of
poly-ubiquitin-aggregated proteins, including a-synuclein
and parkin, an E3 ubiquitin ligase [4-6]. These alterations
are associated with loss of dopaminergic neurons and
resulting motor impairment. Interestingly, rare, heredi-
tary mutations can simulate the same phenotype found
in patients with sporadic parkinsonism. Recent identifica-
tion of mutated genes, including a-synuclein and parkin,
that are associated with hereditary forms of PD has shed
light on the etiology of the disease [7]. Studies show that
many mutations in the parkin gene generally result in
loss of function and are associated with autosomal reces-
sive juvenile parkinsonism (ARJP) [8,9]. Nonetheless, PD
in the vast majority of cases is viewed as a “sporadic” dis-
order without known cause, although oxidative/nitrosa-
tive stress caused by inhibitors of complex I of the
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cides, have recently been implicated [2,10].
Increasing evidence indicates that there may be a link
between oxidative/nitrosative stress induced by reactive
oxygen/nitrogen species (ROS/RNS) and accumulation of
aberrant or misfolded proteins associated with ubiquitin-
proteasome system (UPS) dysfunction [11-15]. This cel-
lular process involves tagging molecules targeted for
degradation with polyubiquitin chains through a series of
reactions carried out by ubiquitin enzymes. Parkin is an
E3 ubiquitin ligase that is believed to play an important
role in the removal and detoxification of abnormally
folded proteins [16]. Parkin has a number of putative
substrates, including synphilin-1 and parkin itself. Dys-
function of parkin results in abnormal ubiquitination and
accumulation of these substrates, which may contribute
to cytoplasmic inclusion formation, impairment in UPS
activity, and the demise of DA neurons [17,18].
Emerging evidence suggests that oxidative/nitrosative
stress-induced mitochondrial as well as UPS dysfunction
play pivotal roles in the etiology of many degenerative
disorders [13,19,20]. Recent reports from our laboratory
and others demonstrated that parkin is S-nitrosylated by
excessive nitric oxide (NO) both in vitro and in vivo
[21,22]. This reaction transfers an NO group to critical
cysteine thiol(s) to regulate parkin’s E3 ubiquitin ligase
activity, trigger aberrant protein accumulation, and con-
tribute to neuronal death in PD. Here, we extend these
findings to oxidative attack on parkin leading to sulfina-
tion (-SO2H)/sulfonation (-SO3H) reactions.
Results
Protein sulfonation recognized in vitro by an antibody
raised against per-sulfonyl-BSA
To investigate protein posttranslational modifications by
oxidation, we generated a broad-spectrum polyclonal anti-
body (pAb) that could identify protein sulfonation by
recognizing epitopes containing cysteine sulfonic acid [Cys
(SO3
-)]-modified residues (see Methods). Due to the extre-
mely small size of the specificity-determining side chain of
sulfonated cysteine (i.e., methyl sulfonate), a large amount
of antigen containing multiple potential epitopes was
deemed necessary to boost immunoreactivity for antibody
generation. Potential epitopes of interest included the Cys
(SO3
-) side chains together with the adjacent peptide
bonds, or pairs of adjacent sulfonated cysteines. Our strat-
egy was to oxidize the 35 cysteine residues in BSA to gen-
erate per-sulfonyl-BSA, containing up to 35 peptide Cys
(SO3
-) groups in various protein sequence environments.
The synthesis of per-sulfonyl-BSA was performed follow-
ing a protocol described previously [23]. Using the anti-
body thus generated, we initially examined putative
sulfonation of a number of cysteine-containing proteins
after oxidative stress engendered by H2O2 in vitro.D o t
blots with various amounts of BSA were used to examine
the dose-dependence of oxidized proteins recognized by
the sulfonation pAb (Figure 1A). Next, immunoblot analy-
sis with the sulfonation pAb revealed that an increase in
BSA sulfonation correlated to the concentration of H2O2
that BSA was exposed to (Figure 1B).
Validation of the sulfonation antibody by in vitro
competition assays
To further assess the specificity of the sulfonation anti-
body in vitro, we examined another known cysteine-con-
taining protein, protein-tyrosine phosphatase 1B
(PTP1B), which has cysteine residues that are known to
be oxidized [24]. We used H2O2 to induce sulfonation of
PTP1B and then conducted a competition assay to test
for the ability of structurally related amino acids to com-
pete with the cysteic acid epitopes on PTP1B for binding
to the anti-sulfonation pAb. We found that there was an
approximately 50% increase in PTP sulfonation (PTP-
SO3H) after exposure to 200 μMH 2O2 in vitro (Figure
1C and 1D). Free l-cysteic acid (Cys-SO3H) competed
virtually completely with PTP-SO3H for antibody bind-
ing. In contrast, a structurally-related amino acid with
negative charges, l-cysteine sulfinic acid (Cys-SO2H),
competed less well for anti-sulfonation pAb binding.
Taken together, these results suggest that the sulfonation
antibody was able to recognize oxidant-induced protein
sulfonation in a variety of peptide environments, poten-
tially representing a “pan-sulfonation antibody”.
ROS-induced parkin sulfonation observed in vitro and in
vivo
To investigate parkin oxidation, we used the sulfonation
pAb that we had generated to initially examine parkin sul-
fonation in vitro after oxidative stress engendered by
H2O2. To further ensure the specificity of the antibody in
identifying sulfonated proteins, we employed another well-
studied antibody, which recognizes solely sulfonated per-
oxiredoxin (Prx-SO3H) [14], as a positive control (Figure
1E). Immunoblot analysis revealed that H2O2 increased
parkin sulfonation in vitro in a dose-dependent manner
(Figure 1F). Taken together, these results suggest that our
“pan-sulfonation antibody” may recognize various sulfo-
nated proteins because it was able to react with proteins
containing multiple amino-acid sequences surrounding
the sulfonated cysteine residue. To test for the presence
and effect of sulfonated parkin in cell-based models of PD,
we used either parkin-overexpressing SH-SY5Y cells
exposed to toxic levels of the mitochondrial complex I
inhibitor–MPP
+, or primary cultures of striatal neurons
exposed to the pesticide rotenone. We detected ROS gen-
eration in these models with two fluorogenic probes, the
cell-permeable fluorogenic dye chloromethyl-2’,7’ dicho-
lor-dihydrofluorescein diacetate (CM-H2DCFDA, DCF) or
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based models displayed significant increases in ROS, while
pretreatment with cell-permeable catalase, a specific
reductase of H2O2, reduced ROS production and pro-
tected dopaminergic neurons from death (Figure 2A-2C
and Additional file 1, Figure S1A). We also quantified the
increase in DCF fluorescence intensity following MPP
+
exposure using a Synergy 4 microplate reader (BioTek,
Winooski, VT) and obtained results (Additional file 1, Fig-
ure S1B) similar to those previously observed under fluor-
escence microscopy in a report linking ROS generation to
MPP
+ exposure [25]. Next, parkin-overexpressing SH-
SY5Y cells exposed to MPP
+ were lysed into “Soluble” and
“Insoluble” fractions. We enriched for recombinant myc-
parkin with anti-myc antibody, and found evidence that
exposure to MPP
+ resulted in a significant increase in par-
kin sulfonation in the “Insoluble” fraction. Pretreatment
1 hour prior to MPP
+ exposure with cell-permeable cata-
lase attenuated sulfonation and aggregation of parkin into
the insoluble fraction (Figure 2D and 2E). These findings
suggest that oxidative stress induced by MPP
+ results in
parkin sulfonation and aggregation.
MS analysis of parkin oxidation
It is most important to link structure with function, that
is, to identify the critical residues in parkin whose oxida-
tive state regulates the E3 ligase activity. Previous studies
of parkin function utilized a predominantly genetic
approach and focused on various point mutations of par-
kin found in familial PD patients [17,26-28]. Such a “bot-
tom-up” approach limits the study to known mutations,
and mutations of some of the cysteine-containing
enzymes were more arbitrary and lacked genetic support.
Therefore, we took an unbiased “top-down” approach by
using liquid chromatography MS (LC/MS)-based com-
prehensive analysis to determine post-translational modi-
fications of cysteine residues in parkin exposed to ROS.
Full-length recombinant human parkin was exposed
to various concentrations of H2O2 in vitro, followed by
in-solution and in-gel trypsin digestion. The resulting
tryptically-digested peptides were subjected to two com-
plementary LC/MS platforms - high resolution nanoLC
quadrupole time-of-flight (Q-TOF) MS and high
throughput nanoLC ion trap tandem MS (see MS work-
flow in Additional file 1, Figure S2), as we have described
Figure 1 H2O2-induced cysteine protein sulfonation observed in vitro. (A) Dot blot analysis of anti-sulfonation antibody to show dose-
response to BSA sulfonation. (B and C) Immunoblot detection with anti-sulfonation pAb of sulfonated purified BSA or PTP1B after oxidative
challenge with H2O2. BSA or PTP1B (10 μM) was exposed to 20 or 200 μMH 2O2 for 30 min. For the competition assay, the anti-sulfonation pAb
was incubated with 1 mM cysteic acid or cysteine sulfinic acid at RT for 2 hours prior to the incubation with the membrane. (D) Quantification
of the competition assays for PTP1B sulfonation. Sulfonation competition was analyzed by normalizing to the intensity of PTP1B sulfonation (PTP-
SO3H) without H2O2 exposure. Data are expressed as mean ± SEM, n =3 ;* p < 0.05 vs. PTP- SO3H by post-hoc ANOVA. (E) Detection of
sulfonated Prx from cells under oxidative stress induced by H2O2. Neuroblastoma SH-SY5Y cells were exposed to H2O2, followed by
immunoblotting with antibodies against per-sulfonyl-BSA, Prx-SO3 and Prx, respectively. Both anti-sulfonation antibodies detected a similar level
of sulfonated Prx (Prx-SO3H). (F) Parkin sulfonation after oxidative stress in vitro. Recombinant parkin was exposed to 20 or 200 μMH 2O2 for 30
min, resulting in sulfonation by immunoblot analysis.
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into a DeCyder™ MS-compatible format [30]. DeCyder™
MS allows for quantitative proteomics analysis to com-
pare the retention time and m/z value of each identified
peak observed in two different LC/MS runs. The MS
data generated from either Q-TOF or ion trap were com-
pared to confirm the similarity of their elution profiles.
Differentially sulfinated/sulfonated peptides were detected
by comparing sample intensity maps and peaks of interest
(m/z values), selected as precursor ions for subsequent
peptide identification and quantification.
We used DeCyder™ MS for multi-spectrum quantita-
tive MS analysis and examined the stoichiometry of the
cysteine modifications of parkin based on their chroma-
tography retention time and relative intensity of the
identified masses. Q-TOF MS data were displayed in
DeCyder™ “2D gel” format with insets showing higher
resolution of the parkin RING-I domain peptide,
“SPVLVFQCNSR” (Figure 3A-3D). This tryptically-
digested parkin peptide was further confirmed by ion
trap tandem MS to contain a double-charged ion with a
carbamidomethyl (CAM)-modified cysteine (represent-
ing alkylation of the free cysteine thiol group by iodioa-
cetamide (IAM) prior to trypsin digestion) at m/z 654.7
(Figure 3G), or sulfonated (SO3H) cysteine at m/z 649.4
(Figure 3H). The sulfinated/sulfonated cysteine-modified
Figure 2 Oxidative stress-induced parkin sulfonation observed in vivo.( A )M P P
+-induced ROS generation detected by the fluorogenic
probe DCF in parkin-overexpressing SH-SY5Y cells. Catalase attenuated ROS production in cells exposed to MPP
+. (B) ROS production induced by
rotenone in a cell-based model of PD in primary striatal neurons. After exposure to 100 nM rotenone for 4 hours, 1 μM HEt was added for 30
min to assess ROS. Then the cells were fixed and immunostained for specific neuronal markers (both MAP2 and NeuN, purple), dopaminergic
cells (TH, green), and nuclear DNA (Hoechst, blue). Scale bar, 10 μm. (C) Quantification of ROS intensity by deconvolution microscopy. Rotenone
exposure led to ROS production and administration of catalase prior to rotenone reduced ROS generation. Data are expressed as mean ± SEM, n
=3 ;* p < 0.05 against Control;
#p < 0.05 for Rotenone vs. Rotenone + Catalase by post-hoc ANOVA. (D) Parkin sulfonation in SH-SY5Y cells
exposed to MPP
+. Cell lysates were subjected to immunoprecipitation with anti-myc antibody (myc-IP). Exposure of parkin-overexpressing SH-
SY5Y cells to 200 μM MPP
+ for 18 hours resulted in a significant increase in parkin sulfonation in the “Insoluble” fraction. Administration of
catalase 1 hour prior to MPP
+ exposure prevented parkin sulfonation. Additional bands when probing for sulfonated parkin appeared only in the
“Insoluble” fraction. (E) Parkin sulfonation was quantified by normalizing the intensity of sulfonated parkin to total parkin. Data are expressed as
mean ± SEM, n =4 ;* p < 0.01 for MPP
+ vs. Control;
#p < 0.01 for MPP
+ vs. MPP
+ + Catalase by post-hoc ANOVA.
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Page 4 of 15peptides in H2O2-exposed parkin were compared to the
vehicle-treated control and calculated by the DeCyder™
MS PepMatch module. Such quantitative DeCyder™ MS
analysis revealed that the sulfonated “SPVLVFQCNSR”
peptide (Figure 3F) was not found in the spectra of the
vehicle-treated control (Figure 3E). Overall, persistent
sulfinated/sulfonated cysteine-containing peptides identi-
fied in the H2O2-exposed parkin by Q-TOF MS and ion
trap MS/MS are listed in Table 1 and Table 2, respec-
tively. There 63.6% of the sulfinated/sulfonated cysteine-
containing peptides were only found in the H2O2-
exposed parkin. Next, we compared the identified peptide
oxidations (sulfination or sulfonation) of parkin with the
sites of parkin mutations found in rare familial cases of
PD (Figure 4). Almost three quarters (73%) of the sulfi-
nated/sulfonated cysteines in parkin were identified in
the RING and IBR (In-Between-RING) domains, indicat-
ing that these regions were highly reactive with ROS (Fig-
ure 4A). Among these identified cysteines in parkin
(shown in Figure 4A), six cysteine residues (C
212,C
253,
C
268,C
289,C
431,a n dC
441) were previously identified
from the UniProt archive (http://www.uniprot.org/uni-
prot/O60260) as bearing point mutations related to rare
familial PD (Figure 4B). Mutations of these cysteines
alter parkin solubility, intracellular localization, and sen-
sitivity to stress [27,28]. These results are consistent with
the notion that the RING and IBR domains contain
regions undergoing cysteine modification during oxida-
tive stress that modulate parkin E3 ligase activity and
affect ubiquitination-mediated protein degradation, thus
contributing to parkin aggregation. Moreover, these find-
ings suggest that sulfonation of these cysteine residues in
the more common sporadic cases of PD may mimic the
effect of rare mutations observed in familial PD.
Oxidative stress induces parkin auto-ubiquitination and
aggregation in cell-based and in vivo animal models of
PD
We next examined whether the ubiquitin E3 ligase activ-
ity of parkin was affected by oxidative stress/ROS. We
found that exposure of parkin-overexpressing SH-SY5Y
cells to H2O2 resulted in increased auto-ubiquitination
Figure 3 MS analysis of H2O2-induced parkin sulfonation. (A) - (F) DeCyder™ MS analysis of high-resolution nanoLC/ESI Q-TOF MS spectra
for recombinant GST-parkin. Full length GST-parkin was exposed to H2O2 (B, D, F and H) and compared to vehicle-treated control (A, C, E and
G). MS spectra displayed in DeCyder™ 2D gel format with insets showing higher resolution of MS datasets (A and B), and converted into “3D”
format (C and D) representing the alkylated peptide
246SPVLVFQCNSR
256. MS spectral analysis revealed that the sulfonated peptide [
246SPVLVFQC
(SO3H)NSR
256] (F) was not found in the vehicle-treated control (E). Marked blue frames indicate the identified peptides by tandem MS. (G) and
(H) Peptide
246SPVLVFQCNSR
256 identified by high-sensitivity MS/MS ion trap as a double-charged ion with a carbamidomethyl (CAM)-modified
cysteine at m/z 654.7 (G) or sulfonated (SO3H) cysteine at m/z 649.4 (H). Both spectra show characteristic “y“ and “b“ series ions. Red asterisks (*)
indicates ions that contain the modified cysteine residue.
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later, reflecting a biphasic effect (Figure 5A). Previously,
we reported a similar biphasic pattern in parkin activity
after exposure to NO [21]. One possible explanation for
this biphasic action is that the free radical modification
of parkin initially activates its E3 ubiquitin ligase activity,
and the resulting auto-ubiquitination subsequently leads
to its inactivation. Excessive ubiquitinated proteins can
potentially overwhelm the proteasome and result in aber-
rant protein accumulation, as has been observed with
parkin in LBs of PD patients [4,15].
Emerging genetic studies indicate that a large number
of familial PD-linked point mutations of parkin alter its
solubility in cells [11,17,26-28]. We thus investigated if
the decrease in parkin solubility that we observed in
sporadic cases of PD resulted in part from oxidative
stress-induced perturbations in the redox state of par-
kin, producing sulfonation. We studied whether such
oxidative stress could affect the cellular localization of
parkin in both cell-based and animal PD model systems.
We found that parkin-overexpressing SH-SY5Y cells
exposed to MPP
+ exhibited a dramatic increase in par-
kin aggregation (Figure 5B and 5C). Administration of
catalase prior to MPP
+ exposure prevented the aggrega-
tion of parkin, consistent with the notion that H2O2-
mediated sulfonation of parkin affects its aggregation
state. To confirm that the MPP
+-induced parkin sulfo-
nation (as shown in Figure 2D and 2E) resulted in par-
kin aggregation via oxidative stress, we exposed parkin-
overexpressing SH-SY5Y cells to various concentrations
of H2O2. Proteins were extracted and separated into
“Soluble” and “Insoluble” fractions. These fractions were
then subjected to SDS-PAGE and immunoblot analysis
to detect parkin. We found a significant increase in par-
k i ni nt h e“Insoluble” fraction and a decrease in the
“Soluble” f r a c t i o ni nH 2O2-treated SH-SY5Y cells
Table 1 DeCyder MS analysis for Q-TOF MS of recombinant parkin exposed to H2O2
Domain (Residue #) Peptide Sequence Monoiostopioc Mr Calculated
Observed
Modifications Ratio
RING I
235NITCITCTDVR
245 1326.59 1326.56 Cys-CAM (C); Cys-SO2H (C) 13.2
(238 - 293)
235NITCITCTDVR
245 1333.55 1333.62 2 Cys-SO3H n/a
235NITCITCTDVRSPVLVFQCNSR
256 2605.19 2605.18† Cys-CAM; Cys-SO2H; Cys-SO3H n/a
246SPVLVFQCNSR
256 1296.61 1296.58 Cys-SO3H n/a
257HVICLDCFHLYCVTRLNDR
275 2367.09 2367.19* Cys-SO3H 3.6
IBR
350VTCEGGNGLGCGFAFCRECK
369 2154.86 2154.90 Cys-CAM; Cys-SO3H n/a
(294 - 417)
370EAYHEGECSAVFEASGTTTQAYR
392 2554.06 2554.09 Cys-SO3H n/a
RING II
428NGGCMHMK
435 956.31 956.33 2 Oxidation (Met); Cys-SO3H n/a
(418 - 449)
428NGGCMHMKCPQPQCR
442 1882.70 1882.77 2 Cys-CAM; 2 Oxidation (Met); Cys-SO3H n/a
436CPQPQCR
442 862.34 862.40 Cys-SO2H n/a
Others
130DSPPAGSPAGRSIYNSFYVYCK
151 2410.09 2410.15 Cys-SO2H (C) 8.1
(1 - 237)
171QATLTLTQGPSCWDDVLIPNR
191 2375.14 2375.15 Cys-SO3H (C) n/a
192MSGECQSPHCPGTSAEFFFK
211 2236.89 2236.94 Cys-SO3H (C) 69.1
192MSGECQSPHCPGTSAEFFFK
211 2309.90 2309.93 Cys-CAM (C); Oxidation (Met); Cys-SO3H (C) n/a
Notes: GST-parkin was exposed to 10 μM (unmarked), 50 μM (*), or 200 μMH 2O2 (†). To compensate for intensity differences between elution profiles of
individual experiments, normalization was performed using the measured intensity distribution of the entire peptide population. Our development of this
algorithm represents a novel function of DeCyder MS v2.0. The ratio of peptide modification was calculated as the intensity of H2O2-exposed parkin compared to
vehicle-treated control. Peptide sequences in these experiments are determined by mass fingerprint. Legend: n/a, not applicable (since peptide modifications
were only identified for the H2O2-exposed samples); IBR, in-between RING domain; CAM, Carbamidomethyl; Cys, cysteine; Met, methionine.
Table 2 DeCyder MS analysis for ion trap MS/MS of recombinant parkin exposed to H2O2
Domain (Residue #) Peptide Sequence Observed (m/z) Monoiostopioc Mr Calculated Observed Ratio
RING I
246SPVLVFQC(SO2H)NSR
256 640.91
2+ 1280.62 1279.81 n/a
(238 - 293)
246SPVLVFQC(SO3H)NSR
256 649.42
2+ 1296.61 1296.83 n/a
IBR
349KVTCEGGNGLGC(SO3H)GFAFCR
366 623.31
3+ 1865.79 1866.91 3.53
(294 - 417)
350VTC(SO2H)EGGNGLGC(SO3H)GFAFCREC(SO2H)K
369 721.51
3+ 2161.82 2161.50 n/a
RING II
421C(SO3H)HVPVEK
427 421.93
2+ 842.40 841.84 13.15
(418 - 449)
428NGGC(SO2H)MHM(Oxidation)KCPQPQC(CAM)R
442 897.89
2+ 1793.69 1793.77 n/a
Others
90NAAGGC(SO3H)EREPQSLTR
104 819.02
2+ 1635.73 1636.03 5.20
(1 - 237)
212C(SO3H)GAHPTSDKETPVALHLIATNSR
234 822.40
3+ 2465.20 2464.17 1.65
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occurred in a dose-dependent manner with regard to
hydrogen peroxide exposure (Additional file 1, Figure
S3).
To recapitulate the effects of exposure of neurotoxins
in vivo, we injected 1 mg/kg/day of rotenone intraperi-
toneally (ip) into rats for 5 days. We found an increase
in inclusion body-like parkin immunoreactivity in the
Figure 4 Mapping locations of parkin oxidation in comparison to parkin mutations found in PD patients. Parkin (PARK2, UniProt 060260;
NCBI AB009973) with 465-aa residues and its various domains indicated [Ubiquitin-like (Ubl), RING I and II, and in-between RING (IBR) domains].
(A) Sulfonated peptides of parkin were identified by either Q-TOF and/or Ion trap MS/MS, and labeled by “─” corresponding to the location of
their sequence. Complementary MS analysis demonstrated that the identified cysteine residues in peptide fragments of parkin in the RING and
IBR domains (16/22 = 73%) were highly reactive with ROS and formed sulfination/sulfonation derivatives of cysteine. (B), Parkin mutations
identified in patients with familial Parkinson’s disease (http://www.uniprot.org/uniprot/O60260), revealing high homology with modifications
induced by oxidative stress.
Figure 5 Oxidative stress-induced parkin auto-ubiquitination and aggregation in PD cell-based and animal models. (A) Auto-
ubiquitination of parkin examined in parkin-overexpressing SH-SY5Y cells exposed to H2O2.H 2O2 induced dose-dependent and biphasic effects
on parkin activity with an initial increase in activity at 2 hours followed by a decrease in activity by 6 hours. (B) and (C) H2O2 involvement in
MPP
+-induced parkin aggregation in parkin-overexpressing SH-SY5Y cells. Cells plated onto cover slips in 24-well culture plates were
immunostained with anti-myc mAb for parkin followed by second antibody conjugated to Cy3 fluorescence dye. Cells were then counterstained
for nuclear DNA with Hoechst dye 33342. Inset: Higher magnification of cells showing parkin immunoreactive aggregates after MPP
+ exposure.
Data are expressed as mean ± SEM; n =3 ,* p < 0.01 for MPP
+ vs. Control;
#p < 0.01 for MPP
+ vs. MPP
+ + Catalase by post-hoc ANOVA. Catalase
protected parkin from aggregation in parkin-overexpressing SH-SY5Y cells exposed to MPP
+, indicating that H2O2-mediated parkin sulfonation
may play a role in formation of parkin aggregates. (D) Increased parkin aggregation (arrows) in striatum of rats exposed to rotenone. Inset: High-
power view showing parkin immunoreactive aggregates. (E) Increased parkin aggregation in monkeys exposed to MPTP. hNSCs transplanted into
MPTP-lesioned monkeys appeared to diminish parkin aggregation (arrow) in the host nigrostriatal system including substantia nigra, similar to
that of nonlesioned monkeys with or without hNSCs. Scale bar: D, 100 μm; E, 50 μm.
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treated controls (Figure 5D). We observed a similar pat-
tern of parkin immunoreactivity in aggregates from
monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) (Figure 5E), consistent with our
prior findings for a-synuclein aggregates in the nigros-
triatal system [31]. Moreover, human neural stem cells
(hNSCs) transplanted into MPTP-lesioned monkeys
appeared to diminish parkin aggregation in the host
substantia nigra, similar to that of nonlesioned monkeys
with or without hNSCs (Figure 5E).
Selective increase in insoluble parkin levels and
sulfonation in idiopathic PD brains
Previously, we and others demonstrated that nitrosative
stress induced by RNS affects parkin E3 ubiquitin ligase
activity [21,22]. This alteration in E3 ligase activity may
contribute to LB formation with the accumulation of
insoluble, aberrant proteins including parkin and its
substrates [4,15,32]. In the present study, since we
found that oxidative stress induced by ROS also affects
parkin E3 ligase activity, we asked if such insult might
also affect aberrant parkin accumulation in idiopathic
PD. We initially examined brain tissues from human
patients with LB dementia compared to control brains
from patients dying of non-CNS causes (Additional file
1, Table S1). Brain tissue was extracted and separated
into “Soluble” and “Insoluble” fractions. These fractions
were then subjected to SDS-PAGE and immunoblot
analysis to detect parkin. We found a significant
increase in parkin in the insoluble compared to the
soluble fraction of brains obtained from patients with
PD and diffuse LBs (Figure 6A and 6B). Note that in PD
compared to control brains, the absolute level of parkin
increased in the insoluble fraction representing an
increase in aggregated parkin.
Next, we examined human postmortem brain tissue
for immunodetection of parkin sulfonation in order to
demonstrate pathophysiological relevance of increased
sulfonation to parkin insolubility in PD. To obtain suffi-
cient tissue for the analysis, we pooled tissue lysates
from two cases in each lane on SDS-PAGE for analysis
of parkin sulfonation via immunoblot (Additional file 1,
Table S2). We found that parkin sulfonation in the
“Insoluble” fractions was significantly increased in the
PD brains compared to the controls (Figure 6C and 6D).
These results demonstrate a significant correlation
between increased sulfonation and insoluble parkin in
PD brains.
Discussion
Epidemiological studies indicate that parkinsonism is the
most prevalent movement disorder, manifesting multiple
risk factors, and predominantly affecting the aged
population. Pathogenesis is strongly associated with
both genetic susceptibility and environmental factors.
Current etiologic hypotheses concerning ‘idiopathic’ PD
favor genetic susceptibility-by-environment (GxE) inter-
actions [7,10]. In the past decade, genetic studies have
shown that relatively rare, inherited mutations cause
familial forms of the disease; these studies have also pro-
vided important insights into the role of molecular net-
works in the development of hereditary as well as
sporadic PD. Emerging evidence suggests that oxidative/
nitrosative stress, possibly due to pesticide exposure
[10], may serve as a primary event in PD pathogenesis
for the more common sporadic or idiopathic form of
P D .R e c e n ts t u d i e sh a v es u g g e s t e dt h a to x i d a t i v e / n i t r o -
sative stress may interfere with normal function of the
UPS in PD [5,15,33-35]. However, direct evidence for
protein modification by free radicals resulting in DA
neurodegeneration is limited [36]. In the present study,
our direct detection of sulfonated derivatives and subse-
quent aggregation of parkin in cell-based PD model, an
increase in aggregated parkin in rats and primates
exposed to mitochondrial complex I inhibitors and in
PD brains, in conjunction with finding that parkin func-
tion is regulated by ROS, yields mechanistic insight into
the chemical reactions of parkin under oxidative stress
and their effect on UPS impairment. Conversely, UPS
dysfunction has been suggested to cause oxidative/nitro-
sative stress [37]. Thus, these two processes may
develop into a vicious cycle that contributes to aberrant
protein accumulation and neurodegeneration in PD.
Here we utilized an unbiased, “top-down” mass spectro-
metry approach combined with molecular and cell biology
methods to elucidate the chemical nature of the posttran-
slational modifications (PTMs) of cysteine residues in par-
kin in response to environmental insults. With this
approach, we provide evidence specifically linking these
PTMs to parkin function. Initially, we discovered parkin
sulfonation in vitro in response to exposure to pathological
concentrations of H2O2, as well as in cells exposed to MPP
+. We documented parkin sulfonation by immunoblot
analysis using a newly developed antibody against sulfo-
nated peptides, and found that sulfonated parkin was
significantly increased in the “Insoluble” fraction of cells
exposed to MPP
+. Catalase significantly reduced sulfo-
nated parkin to levels approximating normal conditions in
control cells.
We documented that environmental insults, including
the mitochondrial complex I inhibitors MPP
+, rotenone,
or other pesticides, increase levels of oxidative stress, at
least in part, in the form of H2O2. We further found
that pathological levels of H2O2 produce a vicious cycle
of increased and then decreased E3 ligase activity.
Under these conditions of oxidative stress, we also
observed inclusion body-like aggregates of parkin by
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cells. As in vivo confirmation of these findings, we
observed an increase in the amount of aggregated parkin
immunoreactivity in the striatum of rotenone-exposed
rats and in the nigrostriatal system of MPTP-lesioned
monkeys. hNSCs transplanted into MPTP-lesioned
monkeys seem to reduce parkin aggregation in the host
substantia nigra. This finding, in parallel with immuno-
histochemistry in the striatum of rotenone-exposed rats,
suggests that hNSC transplants offer an opportunity to
ameliorate parkin’s ubiquitin ligase function by attenuat-
ing parkin aggregation, which would otherwise render
the protein dysfunctional. Additionally, we found that
parkin solubility was significantly decreased in human
postmortem PD brains compared to control brains with-
out CNS pathology. Moreover, we demonstrate that an
increase in the level of sulfonated parkin correlates with
the insolubility of parkin in human PD brains, suggesting
pathophysiological relevance of parkin sulfonation in PD.
However, there is a caveat in this finding in that we
could not demonstrate direct evidence for parkin sulfo-
nation by immunoprecipitation since none of the parkin
antibodies available to us weres u i t a b l ef o ri m m u n p r e c i -
pitation. There are at least three possible reasons pre-
venting us from isolating parkin by immunoprecipitation:
(1) We have only limited amounts of postmortem human
PD brain to start with, especially from the dopamine
fiber-rich regions of the corpus striatum (mainly
caudate); (2) The amounts of “Soluble” parkin available
for immunoprecipitation are relatively low compared to
SDS or urea-dissolved “Insoluble” p a r k i n ;a n d( 3 )I ti s
often observed that SDS or urea used on insoluble pro-
teins may interfere with the ability of the antibodies to
immunoprecipitate. Thus, this type of immunoprecipita-
tion experiment is not feasible with current methods.
Nonetheless, our findings on tissue lysates do show a sig-
nificant correlation between increased sulfonation and
insoluble parkin in human PD postmortem brains.
Using complementary MS strategies ─ high-resolution
Q-TOF MS and high-throughput ion trap MS/MS ─ we
mapped the PTMs of parkin under conditions of oxidative
stress and encountered sulfination/sulfonation of specific
cysteine residues. We found that the RING and IBR
cysteine-rich domains manifested these oxidized modifica-
tions. These PTMs modulated parkin E3 ligase activity,
affected ubiquitination-mediated protein degradation, and
contributed to parkin aggregation. Prior mutagenesis
experiments on parkin causing mutation-induced protein
misfolding have demonstrated that Cys residues both
within and outside of the RING-IBR-RING domain are
important in maintaining protein solubility [27,28,38]. The
two putative sites of S-nitrosylation on parkin, Cys
241 and
Cys
260, which were first reported by our group [21] and
others, match the predicted S-nitrosylation consensus
motif, making them the most likely candidates for physio-
logical modification. S-nitrosylation may also promote
Figure 6 Selective increase in insoluble parkin levels and sulfonation in idiopathic PD brains. (A) The “Soluble” and “Insoluble” fractions of
brain tissue lysates from the caudate nucleus were blotted for parkin immunoreactivity with PRK8 monoclonal antibody. Immunoblotting
revealed that the levels of parkin were significantly increased in the caudate of sporadic PD patients compared to controls. (B) Relative amount
of parkin normalized to actin. Data are expressed as mean ± SEM, n =6 ;* * p < 0.01 by post-hoc ANOVA. (C) The “Insoluble” fraction of tissue
lysates from postmortem human brains of either normal control subjects or sporadic PD cases were immunoblotted for parkin sulfonation.
Pooled brain tissue lysates were obtained from 12 patient samples (see subject information in Additional file 1, Table S2). Increased parkin
sulfonation was observed in PD compared to Control. (D) Quantification of parkin sulfonation by normalizing the intensity of sulfonated parkin
to total parkin. Data are expressed as mean ± SEM, n =3 ;* p < 0.05 by post-hoc ANOVA.
Meng et al. Molecular Neurodegeneration 2011, 6:34
http://www.molecularneurodegeneration.com/content/6/1/34
Page 9 of 15further oxidation reactions such as sulfonation, as
observed in the present study.
With regard to related nitrosylation/oxidation reac-
tions, S-nitrosylation of Prx interrupts the normal redox
cycle of Prx in detoxifying ROS, and thus results in
accumulation of cellular peroxides [14]. Therefore,
S-nitrosylation of Prx may also contribute to oxidative
stress-induced neuronal cell death in PD. These pre-
viously published results from our group suggest that
the mechanism of interplay between SNO-Prx and Prx-
SO3H may be different from that of SNO-parkin and
parkin-SO3H.
A variety of markers and indices in PD patients and
animal models have suggested that derangements in
mitochondria complex I activity and consequent oxida-
tive/nitrosative stress are important contributors to
sporadic PD [39]. At least three mitochondrial complex I
i n h i b i t o r s ,i n c l u d i n gM P T P ,p a r a q u a ta n dr o t e n o n e ,a r e
capable of simulating many features of sporadic PD and
provide valuable models for PD investigation [10,40].
Impaired mitochondrial complex I leads to increased oxi-
dative stress, free radical formation, and reduction in
ATP formation, rendering neurons more vulnerable to
glutamate-related excitotoxicity. ROS/RNS, such as
endogenous H2O2 and NO, are implicated in the patho-
genesis of PD. In fact, similar to ROS, NO can lead to
secondary oxidative modification on parkin in vivo
[21,22], and pathological levels of RNS in combination
with ROS can produce synergistic cytotoxic effects by
irreversibly S-nitrosylating and then further oxidizing
proteins as well as other cellular constituents [41,42].
Increased oxidative stress contributes to a cascade lead-
ing to DA neuron degeneration predominantly in the
pars compacta of the substantia nigra. The occurrence of
oxidative stress in PD is supported by both postmortem
analyses and studies demonstrating the capacity of oxi-
dizing toxins to induce nigrostriatal degeneration [43,44].
Previous reports have suggested that ROS/RNS can affect
proteasomal function [19,26,33,45,46]. Indeed, recent stu-
dies by our laboratory and others have shown that nitro-
sative stress can modulate parkin E3 ubiquitin ligase
activity and subsequently impair UPS function [21,22].
Parkin may form a functional complex with PINK1 and
DJ-1 [47], but dysfunctional ubiquitination in the face of
oxidative/nitrosative stress results in the loss of the
intrinsic neuroprotection mechanism, and thus mimics
familial PD in the absence of mutation of one of the
genes encoding these proteins [21,22]. Moreover, recent
work has shown that PINK1 recruits parkin to the outer
membrane of impaired mitochondria, and parkin heralds
mitophagy through its ubiquitination of outer mitochon-
drial membrane proteins [48]. As ROS and RNS are clo-
sely related and interact with each other, our present
results indicate that oxidative and nitrosative stress act
similarly on parkin activity. Substantial evidence supports
the notion that high levels of basal oxidative stress exist
in the substantia nigra pars compacta in the normal
brain and that these levels are increased in PD.
As we report in the present study, oxidative stress can
lead to sulfonation of the cysteine residues of parkin,
which can affect protein tertiary structure, decrease par-
kin solubility, and affect parkin E3 ligase activity. These
changes may contribute to the etiology of sporadic PD.
Parkin possesses 35 cysteine residues, corresponding to
a cysteine content of 7.5% (human proteomic average is
2.3% [49]). In addition, at least six different cysteine
mutants have been experimentally linked to parkin dys-
function (http://www.uniprot.org/uniprot/O60260).
These findings suggest that cysteine residues in parkin
are essential for its function, including protein folding
and ubiquitination. Yet these cysteines also predispose
this highly-expressed CNS protein to chemical modifica-
tions under nitrosative and oxidative stress, including
S-nitrosylation and sulfonation. We speculate that such
oxidative changes may result in structural changes in
the protein similar to those produced by hereditary
cysteine substitutions linked to parkinsonism, e.g., sub-
stitution of cysteine to Y(212), Y(253), stop(256), G
(289), F(431), or R(441). In fact, we have found evidence
for cysteine residues that are sulfonated in parkin are
associated with aggregation of the protein. Hence, oxida-
tion of structurally or functionally critical cysteine resi-
dues might represent a molecular point of convergence
in the pathogenesis of PD, connecting hereditary muta-
tions that affect parkin solubility and function with
adverse environmental insults resulting in similarly det-
rimental oxidative modifications of parkin at a posttran-
slational level.
Conclusions
In summary, we report here that parkin sulfonation pro-
duces the appearance of LB-like aggregates during oxi-
dative stress from environmental insults. This study
provides mechanistic insight into the action of biologi-
cally significant PTMs that regulate protein degradation
and contribute to neurodegenerative disorders. As
alluded to above, several of the cysteine thiol sulfinated/
sulfonated peptides of parkin identified by our MS tech-
niques were previously reported as mutated parkin
cysteine residues in familial forms of PD. Mutations of
these cysteines alter parkin solubility, intracellular locali-
zation, and sensitivity to stress [27,28]. Thus, we suggest
that PTMs, including S-nitrosylation and subsequent
sulfination/sulfonation [42], may give rise to similar
alterations in tertiary structure as rare hereditary muta-
tions, thus providing a mechanistic link between genetic
and sporadic forms of PD. Understanding the molecular
mechanisms that give rise to these PTMs on parkin
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dant therapies for PD.
Methods
Expression of recombinant parkin
Recombinant parkin was expressed and purified as pre-
viously described [21]. Briefly, full-length parkin cDNA
was cloned into a pGEX-4T-2 vector, and the constructs
transduced into BL21 cells. Expression of recombinant
GST-parkin was induced by isopropyl b-D-1-thiogalac-
topyranoside (IPTG) according to the manufacturer’s
instructions (GE Healthcare, Uppsala, Sweden). After
cell lysis, GST-parkin was purified on a column of glu-
tathione Sepharose beads and further treated with
thrombin to remove GST. Parkin (1 μg) was exposed to
0, 10, or 200 μMH 2O2 at room temperature (RT) for
30 minutes (min) and then immunoblotted to detect
parkin sulfonation.
Generation and evaluation of an anti-sulfonation
polyclonal antibody
A polyclonal antibody (pAb) was developed in order to
recognize diverse epitopes containing cysteine sulfonic
acid [Cys(SO3
-)] derivatives of intact proteins. Unlike
other commercial sulfonation antibodies that react with
only one oxidized protein (for instance of Prx-SO3H), we
attempted to design a polyclonal antibody that would
react with multiple sulfonated peptides. For this purpose,
we reasoned that BSA, which has multiple cysteine resi-
dues, could serve as a scaffold for the generation of sev-
eral sulfonation antigens–per-sulfonyl-BSA. In brief, BSA
(200 mg) was suspended in 8.88 ml of highly purified
DMSO. Then 1 ml of 10 mg/ml iodine in DMSO was
added, followed by 0.12 ml of 36% HCl. The mixture was
then incubated at 45°C for 24 hours while shaking gently.
After cooling to RT, the product was precipitated with
20 ml of cold acetone at 4°C for 1 hour. The precipitate
was washed with 10 ml of acetone twice as above, and
subsequently washed twice with cold methanol at 1-hour
intervals at 4°C. The last precipitate was dried under a
stream of nitrogen.
The final product was analyzed by mass spectrometry
to verify the oxidative BSA modifications. The absence of
reducible thiols in the product thus obtained was con-
firmed by Ellman’s reagent (DTNB). Sulfonated BSA was
used as the antigen and submitted to a commercial ven-
dor, Abgent (San Diego, CA), to generate anti-sulfonation
polyclonal anti-serum from rabbits with an ELISA titer
higher than 1:10,000.
The anti-sulfonated BSA pAb was purified using pro-
tein A/G-agarose. Briefly, rabbit anti-serum containing
the anti-sulfonated BSA pAb was mixed with an equal
volume of 100 mM phosphate buffer (pH 7.4) and incu-
bated with protein A/G-agarose at 4°C for 2 hours. After
washing the beads with 100 mM phosphate buffer, the
anti-sulfonated BSA pAb was eluted five times with
100 μl volumes of 100 mM glycine solution (pH 2.8), fol-
lowed by neutralization of each eluate with 5 μlo f1M
Tris solution (pH 8.3).
Next, we sought to minimize any rabbit anti-serum con-
taining antibodies that recognized the reduced form of
BSA, i.e., BSA that had been reduced and converted to its
CAM derivative by alkylation with IAM. To deplete any
anti-reduced BSA pAb, the eluted anti-serum was incu-
bated with reduced BSA-agarose, prepared as follows: 1 ml
NHS (N-hydroxysuccinimide)-activated agarose was incu-
bated with a 2 ml volume of BSA (10 mg/ml) in 100 mM
phosphate buffer (pH 7.4) for 1 hour at RT; residual BSA
was then removed by centrifugation. Following this step,
2 M ethanolamine (pH 7.4) was added to the beads and
incubated at RT for 15 min. After washing the beads with
50 mM Tris (pH 7.4), 50 mM dithiothreitol (DTT) was
added for 1 hour at RT, followed by washing with 1 mM
DTT. Then 50 mM IAM was added for 1 hour at RT.
Finally, the resulting anti-sulfonated BSA pAb was incu-
bated with an equal volume of reduced BSA-agarose over-
night at 4°C for further purification. After centrifugation,
the supernatant was saved as the anti-sulfonation pAb.
Dot blotting was performed to determine the dose-
response of the pAb to antigen. To further evaluate the
specificity of the anti-sulfonation pAb, competition assays
were performed using chemicals with structures similar to
the envisaged epitopes containing Cys(SO3
-). Briefly,
10 μM BSA or another cysteine-containing protein, such
as recombinant PTP1B in 50 mM Tris (pH 7.4), was
exposed to 20 or 200 μMH 2O2 for 30 min at RT. The
resulting sulfonated BSA or PTP1B was then gel electro-
phoresed and transferred to nitrocellulose membrane for
immunoblotting. The membrane was incubated with anti-
sulfonation pAb at 4°C overnight. For the competition
assays, the anti-sulfonation pAb was incubated with 1 mM
l-cysteic acid or l-cysteine sulfinic acid at RT for 2 hours
prior to immunoblotting.
For cell-based assays to assess the anti-sulfonation
pAb, SH-SY5Y cells were exposed to 200 μMH 2O2, and
the resulting sulfonated proteins in cell lysates were sub-
jected to electrophoresis for immunoblotting with the
pAb. Peroxiredoxin (Prx) and sulfonated Prx (Prx-SO3H;
Lab Frontier, Seoul, Korea) served as controls [14].
Cell-based and animal models of PD
(i) PD cell-based models: Myc-tagged, parkin-overex-
pressing SH-SY5Y cells [21] were grown in Dulbecco’s
modification of Eagle’s Medium (DMEM) containing
10% fetal bovine serum (FBS) and 500 μg/ml geneticin
in a 5% CO2 atmosphere. At 70% confluence, the med-
ium was removed and cells were incubated with the
mitochondrial complex I inhibitor, MPP
+ (Sigma, St.
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cultures of the enriched striatal neurons were prepared
and maintained for 14 days in vitro (DIV), as previously
described [50] with minor modifications. Briefly, to pre-
pare primary cultures, striatal tissues were dissected out
from E16-18 time-pregnant Sprague-Dawley rats and
dissociated in 0.05% trypsin for 35 min at 37°C. Striatal
neurons were seeded in DMEM supplemented
with heat-inactivated FBS and Ham’s F12 (ratio 8:1:1),
24 U/ml penicillin, 24 μg/ml streptomycin, and 24 mM
H E P E S ,p H7 . 4a tad e n s i t yo f0 . 6 7×1 0
6 cells per 35-
mm dish containing poly-l-lysine (PLL, Sigma, St. Louis,
MO) coated glass cover slips. The cultures were
replaced the following day with DMEM supplemented
with 1% B27 neurobasal medium and 0.5 mM gluta-
mate, and incubated in a 5% CO2, 95% air humidified
atmosphere at 37°C. Striatal neurons were exposed to
100 nM rotenone for 4 hours. To prevent H2O2 accu-
mulation, 100 U/ml catalase (Sigma, St. Louis, MO) was
added to the medium 1 hour prior to MPP
+ or rotenone
exposure.
(ii) PD animal models: All animal experiments were
performed as described previously [21] according to
guidelines set by the relevant institutional Animal Care
and Use Committees of the collaborating institutions.
Briefly, Sprague-Dawley rats weighing 200-250 g were
divided into two groups (n = 10 per group) to receive ip
injections of freshly prepared rotenone (1 mg/kg/day in
50% DMSO and 50% polyethylene glycol) or vehicle
only (as the control group) daily for 5 days. MPTP-
lesioned monkey brain slices were generously provided
by Dr. Evan Y. Snyder of the Sanford-Burnham Medical
Research Institute with details of the preparation pre-
viously described [31].
Immunoblotting parkin from fractionated cells and
human brains
Autopsied human brain samples were analyzed following
the guidelines of the relevant Institutional Review Boards.
Cell lysates and PD brain tissue homogenates were
sequentially fractionated as previously described [28,51]
with minor modifications. Myc-tagged, parkin-overexpres-
sing stable SH-SY5Y cells were lysed with 1% Triton X-
100 in phosphate buffered saline (PBS) containing a cock-
tail of protease inhibitors (Sigma, St. Louis, MO) and sedi-
mented at 22,000 g at 4°C for 15 min. Supernatant from
the initial fractionation was harvested as the “Soluble”
fraction, and the remaining pellet was washed once with
1% Triton X-100 in PBS before re-extraction with 1% SDS
in PBS. After sedimentation at 22,000 g for 15 min at RT,
the supernatant was collected as the “Insoluble” fraction.
Equal amounts of protein from the “Soluble” and “Insolu-
ble” fractions were used for immunoprecipitation (IP) with
anti-myc mAb-Agarose (Santa Cruz, CA) in order to
detect parkin. For IP, 1 mg of protein from the “Soluble”
fraction, or 200 μg of protein from the “Insoluble” fraction
diluted 10-fold with 1% Triton X-100 in PBS, was incu-
bated with 40 μl of a 25% slurry of anti-myc mAb-agarose
overnight at 4°C. After washing with 1% Triton X-100 in
PBS on ice, the beads were re-suspended in an aliquot of
SDS sample buffer and the eluant collected for detection
of parkin sulfonation by electrophoresis under reducing
conditions with subsequent immunoblot analysis.
Similarly, brain tissue from PD patients or control sub-
jects without CNS disease was fractionated with 1% Triton
X-100 (designated the “Soluble” fraction) followed by 8 M
urea (the “Insoluble” fraction) in 0.5 M NaCl and 50 mM
Tris at pH 7.4. Equal amounts of protein from the differ-
ent fractions were loaded for immunoblotting with anti-
parkin monoclonal (m)Ab (PRK8, Cell Signaling Tech.
Danvers, MA). For all experiments, protein concentration
was determined with a BCA protein assay kit.
ROS detection and immunocytochemistry
Cellular localization of parkin was examined in cultures by
immunocytochemistry and confocal microscopy, as pre-
viously described [28]. Parkin-overexpressing SH-SY5Y
cells were plated onto cover slips in 24-well culture plates.
After two days, cells were incubated with 200 μMM P P
+ in
FBS-free DMEM for 18 hours or with 100 nM rotenone
for 4 hours, with or without the administration of 100 U/
ml catalase 1 hour prior to exposure to neurotoxins. For
ROS detection, during the final 30 min of exposure to
either MPP
+ or rotenone, 5 μM cell-permeable fluorogenic
dye DCF or 1 μM HEt was applied to the cells, as sug-
gested by the manufacturer. Cells were fixed in 4% parafor-
maldehyde (PFA), permeabilized with 0.1% Triton X-100,
and incubated with anti-myc mAb for parkin, NeuN and
MAP-2 mAb to identify neurons, or anti-tyrosine hydroxy-
lase (TH) antibody for labeling dopaminergic neurons in
primary striatal cultures, followed by second antibody con-
jugated to various fluorescent dyes. Cells were then coun-
terstained for nuclear DNA with Hoechst dye 33342
(Invitrogen, San Diego, CA).
Immunohistology on tissue sections was performed
with standard methods using a primary pAb for parkin
(2132, Cell Signaling Tech, Danvers, MA) at a dilution of
1:500 plus a secondary Ab at a dilution of 1:200 with the
Vector ABC kit (Burlingame, CA). Monkey brain sections
were counterstained with Hoechst 33342. Fluorescent
images were acquired on an Olympus X81 spinning-disc
confocal microscope equipped with a Hamamatsu deep-
cooled monochrome EM camera (C9100-13) and 3I-Sli-
debook™ software analysis package (Denver, CO).
Immunostaining that omitted primary antibody and SH-
SY5Y cells transfected with empty vector pcDNA3.1 were
included as negative controls. To determine the number
of cells containing parkin aggregates, ~200 myc-parkin
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slips per experiment.
Polyubiquitination assays
For cell-based ubiquitination assays, parkin-overexpres-
sing SH-SY5Y cells were transfected with hemagglutinin
(HA)-tagged ubiquitin, exposed to various concentra-
tions of H2O2, and then examined at different time
points. The proteasome inhibitor MG132 (10 μM) was
added to block degradation of poly-ubiquitinated pro-
teins during the assay. Cell lysates were subjected to
immunoprecipitation with anti-myc mAb for parkin, fol-
lowed by Western blotting against HA for ubiquitin.
Mapping PTMs of cysteine residues in parkin
(i) Protein digestion: Recombinant human parkin was
exposed to pathological doses of H2O2 in vitro followed
by in-solution or in-gel trypsin digestion, as described
previously [19,21]. Protein digestion was carried out by
in-solution digestion or by DigestPro in-gel digestion
using a robotic workstation (Intavis, Koeln, Germany).
(ii) High-resolution mass spectrometry: LC-MS ana-
lyses were carried out using a high-resolution (5 ppm) Q-
TOF API-US mass spectrometer (Waters Micromass,
Manchester, UK) with an on-line nanoLC system (LC
Packings, Sunnyvale, CA), as previously described [21].
We used a 75 μmI . D .×1 5c mP e p M a pC 1 8a n a l y t i c a l
column (LC Packings, Sunnyvale, CA) with 3-μm particle
size. Mobile phase A was 2% acetonitrile (ACN)/0.1% for-
mic acid (FA), while mobile phase B was 80% ACN/0.1%
F A .T h eg r a d i e n tw a s2 %~4 0 %m o b i l ep h a s eBi n
75 min, followed by 100% mobile phase B for 5 min. The
flow rate was set at 0.2 μl/min. Mass spectra of untreated
parkin and H2O2-exposed parkin were analyzed for
PTMs, including cysteine alkylation or sulfination
(R-SO2H)/sulfonation (R-SO3H) and methionine oxida-
tion using an in-house Mascot 2.0 server (Matrix Science
Inc., London, UK). The modifications of tryptically-
digested peptides of parkin were further confirmed by
tandem MS spectra analysis as described below.
(iii) High-throughput ion trap tandem MS: We used
packed Picofit capillary column with an integral spray tip
(Picofit, 15 μm tip, New Objective, Woburn, MA) for
reversed-phase nanoLC MS/MS. The column had an
internal diameter of 75 μm, was 15 cm long, and packed
with 5 μm C18 AQUASIL. A linear gradient elution was
used, from buffer A (0.1% FA in water) to 50% buffer A +
50% buffer B (0.1% FA in ACN) in 100 min, and flow rate
was set at 0.2 μl/min. Two ion-trap mass spectrometers
were used for maximizing peptide detection: an LTQ lin-
ear ion trap mass spectrometer (Thermo Electron, San
Jose, CA) and an HCTultra PTM discovery system (Brüker
Daltonics, Bremen, Germany). The instruments were
operated in a data-dependent mode, in which the first and
second strongest ions were sequenced in each cycle with
dynamic exclusion enabled and the collision energy set at
35%. For the nanoLC-MS/MS analysis by using an LTQ
linear ion trap LC/MS, recombinant proteins were
digested with 0.04 μg/μl trypsin for 15 hours. The result-
ing tryptic digests were then on-line separated on a 5-cm
packed PicoFrit capillary column (New Objective,
Woburn, MA) with an Eksigent nanoLC system (Dublin,
CA). Initially, it was eluted with H2O/ACN/FA (98:2:0.1,
v/v/v) for 5 min, then a linear gradient increased ACN to
55% by 60 min, and finally decreased ACN to 2% by 65
min. MS/MS spectra were acquired in the data-dependent
scanning mode with one full scan followed by four MS/
MS scans on the most intense precursor ions with
dynamic exclusion enabled. MS/MS data were then
further analyzed with SEQUEST Sorcerer software (Sage-
N Research, Milpitas, CA).
(iv) DeCyder™ MS analysis: LC/MS data generated by
either Q-TOF MS or ion trap MS/MS were converted
into a DeCyder™ MS v2.0 (GE Bioscience, Uppsala,
Sweden) compatible format, as previously described
[30], and the MS profiles were aligned based on the m/z
and retention time values to ensure the reproducibility
and consistency of the LC spectral profiles. Differentially
sulfinated/sulfonated peptide candidates were detected
a n dq u a n t i f i e db yc o m p a r i n gthe signal intensity maps
generated by DeCyder™ MS software, and peaks of
interest (m/z values and charge states) were selected as
precursor ions for subsequent peptide identification.
Additional material
Additional file 1: Additional Figures and Tables.Figure S1: ROS
production in cellular PD models. (A) ROS production in primary rat
striatal neurons induced by rotenone. After exposure to 100 nM
rotenone for 4 hours, 1 μM hydroethidine (HEt) was added for 30 min to
assess ROS (red). Then the cells were fixed and immunostained for
specific neuronal markers (MAP2 and NeuN, purple), dopaminergic cells
(TH, green), and nuclear DNA (Hoechst, blue). Scale bar, 80 μm. (B)
Quantification of ROS generation in SH-SY5Y cells by fluorescence
microplate reader. MPP
+ exposure led to ROS production. Administration
of catalase prior to MPP
+ exposure reduced ROS generation Values are
expressed as mean ± SEM, n =3 ;* p < 0.05 against Control;
#p < 0.05 for
MPP
+ vs. MPP
+ + Catalase by post-hoc ANOVA.Figure S2: Mass
spectrometry (MS) workflow to identify parkin modifications. GST-parkin
was exposed to H2O2 in vitro, followed by trypsin digestion. The digested
peptides were subjected to on-line nanoLC attached to either high-
resolution Q-TOF MS or high sensitivity ion trap tandem MS analysis.
These LC/MS data were then converted into a DeCyder™™ MS-
compatible format for proteomic comparison (the m/z value of each
identified peak was compared between LC/MS runs).Figure S3:
Decreased parkin solubility in SH-SY5Y cells. Myc-parkin-overexpressing
SH-SY5Y cells were exposed to 0, 0.2 or 1 mM H2O2 for 1 hour. Cell
lysates were separated into “Soluble” and “Insoluble” fractions, followed
by Western blotting against myc to identify parkin. After exposure to
H2O2, the solubility of myc-parkin decreased dramatically in SH-SY5Y cells.
Coomassie blue staining of the gels was used to ensure equal protein
loading.Table S1: List of human brain subjects for parkin
immunoblotting analysis.Table S2: List of human brain subjects for
immunoblotting analysis of parkin sulfonation
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